Fig. 6 | Scientific Reports

Fig. 6

From: RBM47 is a novel immunotherapeutic target and prognostic biomarker in gliomas

Fig. 6

Co-expression of RBM47 and CD163 + macrophages. (A, C, E) UMAP analysis of single-cell sequencing. (B) In the CGGA dataset, the M2 macrophage marker CD163 was enriched in clusters 6 and 8, and RBM47 was also enriched in these two clusters. (D) In the GSE214966 dataset, the M2 macrophage marker CD163 was enriched in cluster 3, and RBM47 was also enriched in this cluster. (F) In the GSE131928 dataset, the M2 macrophage marker CD163 was enriched in cluster 2, and RBM47 was also enriched in this cluster. (G) Immunofluorescence showed CD163 and RBM47 co-expression in glioma samples.

Back to article page